To accelerate the shift to bio-based production and overcome complicated functional implementation of natural and artificial biosynthetic pathways to industry relevant organisms, development of new, versatile, bio-based production platforms is required. Here we present a novel yeast platform for biosynthesis of bacterial aromatic polyketides. The platform is based on a synthetic polyketide synthase system enabling a first demonstration of bacterial aromatic polyketide biosynthesis in a eukaryotic host.
Introduction
An increasing number of chemicals are being produced by environmentally-friendly biobased synthesis 1, 2 to overcome the problems of low-yielding chemical synthesis or solvent-heavy extraction from natural resources, for achieving a sustainable way of life. Unfortunately, development of microbial cell factories for the bio-based production of desired chemicals often requires significant amount of time, resources and efforts to meet industrial demand, hence the shift towards bio-based production is slow. Also in many cases native hosts are not suitable for industrial conditions due to low production level and/or complicated culturing conditions, necessitating the use of a heterologous hosts such as Escherichia coli or yeast 3, 4 . However, production of natural products, such as polyketides, in heterologous hosts has proven difficult or even impossible [5] [6] [7] . To overcome these limitations, standardized, versatile and programmable biosynthesis platforms in genetically traceable, and robust hosts are desired.
Polyketides are a large class of bioactive natural compounds found widely in fungi (type I iterative and type II ), bacteria (mostly type II, but also type I modular and type III) and plants (type III), possessing a variety of biological activities, including antibacterial, anticancer, antifungal, antiviral and many more [8] [9] [10] [11] . As a consequence, polyketides have been, and still are, major leads in drug discovery programs [11] [12] [13] [14] .
The most diverse and widely studied polyketides are originating from bacteria 11 . Complex bacterial aromatic polyketides can be produced through non-reducing polyketide pathways, where two-carbon units (-CH2-CO-, ketides) are polymerized into linear polyketide chains of various length by multicomponent enzyme complexes known as polyketide synthase (minimal PKS), and then can be folded to form aromatic structures [15] [16] [17] . Folding in most bacterial systems is facilitated by aromatases and cyclases, and the resulting products are further modified by other classes of tailoring enzymes that closely interact with the minimal PKS 18 . From the bioengineering point of view, bacterial type II PKS systems offer flexibility in terms of choice from vast amount of aromatases, cyclases and tailoring enzymes to allow for the rational engineering of pathways to form desirable aromatic compounds 19 and to develop programmable polyketide production platforms. Development and optimization of such a production platform in native bacterial hosts can be troublesome due to the lack of genetic tools, production of unwanted toxic metabolites, complicated culturing conditions, and low or conditional production of desired compounds 3, 4, 20 .
Unfortunately, bacterial type II PKSs have not yet proven possible to express in eukaryotes 15 . In contrast, plant (type III) PKSs, that ultimately form aromatic compounds, via linear non-reduced polyketide intermediates, consist of a single enzyme 21 and can be expressed in heterologous eukaryotic hosts to form a polyketide chain of varied length, yet the lack of characterized cyclases, aromatases and tailoring enzymes in plant PKS systems limits the use of type III PKSs for versatile polyketide biosynthesis 22, 23 . Although, recently it was demonstrated that it is possible to functionally combine the activity of plant type III PKS with bacterial type II PKS related cyclase and aromatase in plants and filamentous fungi 23, 24 Here, we describe a first-of-its-kind programmable polyketide production platform in the 
Results

Expression of Act gene cluster in yeast
First, we reconstructed a widely studied actinorhodin pathway 25 by integrating required codon optimized genes into the yeast genome together with its bacterial minimal PKS ( Figure 1A ).
Gene assemblies and genomic integrations were performed in 2-3 steps by first performing in vivo assembly of expression units in Escherichia coli, and second by using our recently developed CRISPR/Cas9 genome engineering techniques to integrate the assembled gene expression units into the yeast genome (Supplementary Table 1 ) 26, 27 . Since actinorhodin and other intermediates in the pathway have color 28 , successful production through the pathway was initially expected to be assessed by visual inspection of engineered yeast. However, from the first designs, no apparent or very modest color was observed in yeast cells harboring actinorhodin pathway (Supplementary Figure 1 ; TC-140, TC-156). To mitigate the lack of (or modest) visual phenotypes we next investigated if all proteins from the Act pathway were successfully expressed using whole cell proteomics. From this analysis it was evident that most of Act proteins were detected except for ActVI-2 (dehydrogenase) and ActI-1 (3-oxoacyl-ACP synthase), the latter of which is needed for the first committed step of the minimal ActPKS (Supplementary Figure 2) . Further, we aimed to elucidate which metabolites, if any, are produced from first generation Act pathway design. Since none of the reported pathway metabolites are commercially available as standards, we performed comparative LC-MS metabolite profiling using wild type S. coelicolor whole cell extract as a standard. This analysis indicated that none of the described intermediates from the Act pathway or Act itself were detected in the engineered yeast strains ( Figure 1B ; TC-140, TC-156), hinting that the Act -type II PKS indeed was not functionally expressed or correctly assembled into a functional PKS in yeast.
Replacement of Act minimal PKS with AaOKS
To overcome the lack of function of type II PKS we replaced the Act minimal PKS with a type III octaketide synthase from plant A. arborescens (AaOKS) 29 , which was described to produce a polyketide product with an identical chain-length as Act. Hence, the second generation production strains were created by replacing the actinorhodin minimal PKS with AaOKS, but retaining the rest anticancer, antifungal, antiparasitic properties, and it is a potential drug target 31, 32 . To further investigate the compound putatively identified as DHK, we performed more thorough analysis including LC-MS/MS, as no standards were commercially available. These results indicated that DHK was indeed being produced in the engineered yeast strain as its MS/MS fragmentation pattern was the same in both engineered yeast strain and S. coelicolor (Supplementary Figure 3) .
Optimization of aromatic polyketide production platform
To optimize the platform strain further for production of type II polyketide compounds, we next integrated a second copy of each of the four genes encoding ActVI-3, ActVI-2, ActVA 
Versatility and programmability of the system
The main goal of this study was to create a versatile and programmable platform for production of bacterial aromatic polyketides. To prove that our polyketide production platform can be engineered to express different polyketide synthesis modules, we replaced several key Act enzymes with enzymes from other Streptomyces species to achieve production of desired products 
Discussion
In summary, we have developed a functional first-of-its-kind eukaryotic production platform for bacterial polyketide derived products by employing a plant type III polyketide synthase to produce compounds originally found only in bacteria. As a proof-of-concept we engineered and optimized our platform in S. cerevisiae to successfully produce a compound identified as bioactive bacterial polyketide DHK. Finally, we further demonstrated versatility and programmability of our system by replacing key enzymes in Act pathway with enzymes from different Streptomyces species to produce desired products. Such characterisation confirms ability of the system to functionalize and produce octaketide derived products in a well-described, eukaryotic production work-horse. We envision our platform to be useful for production of many novel compounds, including novel antibiotics, characterization and functionalization of them, and moreover, sustainable production through cell factories.
Methods
Strains, plasmids and media
The yeast strains used here were isogenic to CEN.PK2-1C. Strains and plasmids are listed in Supplementary Tables 2 and 3 , respectively. Yeast cells were grown in complete medium (YPD)
with 2% glucose and synthetic complete (SC) from Sigma, supplemented with 2% glucose. E. coli strains were propagated in LB medium supplemented with 200 mg of ampicillin, Streptomyces strain was grown in ISP2 medium with 4% glucose.
All primer names and sequences are listed in Supplementary Table 4 .
Plasmid and strain construction
To create polyketide expressing strains large set of genes were integrated by using advanced CRISPR/Cas9 technology 26, 27 . To create expression cassettes, respective genes were codon optimized for yeast and ordered (Integrated DNA Technologies) as gene blocks. Gene blocks were amplified using corresponding primers (Supplementary Table 4 ) and first USER cloned with single or bi-directional promoters to yeast integrative plasmids as described in previously published method 27 . All created integrative plasmids with corresponding expression units are listed in Supplementary Table 3 . By employing previously detailed procedure 27 , all integrative plasmids were linearized and with their corresponding gRNA plasmids transformed to yeast expressing Cas9 for integration of desired genes to the genome. Due to large number of genes to be integrated, this has been processed in 2-3 steps. In a single transformation 4-6 genes were introduced and created strain used for the next round of transformation until all pathway genes were integrated. All the other plasmids and strains were created in the same way as previously described 27 .
Metabolite extraction
Yeast cells were cultured in 50 ml SC selective or YPD medium for 168 hours at 
Whole cell proteomics
The yeast cultures were grown in YPD medium in triplicates. Exponentially growing cells were harvested (totally OD 600 -20) and cell pellets flash-frozen in liquid nitrogen.
To prepare for protein lysis and precipitation, the yeast cell pellets were treated with 0.5 uL then increasing linearly to 65% Buffer A/35% Buffer B over 5.5 minutes. Buffer B was then increased to 80% over 0.3 minutes and held at 80% for two minutes followed by ramping back down to 5% Buffer B over 0.5 minutes where it was held for 1.5 minutes to re-equilibrate the column for the next sample. The data were acquired using Agilent MassHunter, version B.08.02, processed using Skyline version 4.1, and peak quantification was refined with mProphet in Skyline.
All data and skyline files are available via the Panorama Public repository at this link:
https://panoramaweb.org/a-platform-for-polyketide-biosynthesis-using-yeast.url. Data are also available via ProteomeXchange with identifier: PXD013388.
Comparative metabolite profiling by LC-MS and data analysis
LC-MS analysis was performed using a Dionex Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) coupled to a UV/Vis diode array detector (DAD) and a high- LC-MS/MS analysis was carried out using data-dependent MS/MS analysis by analyzing the most intense ions form the full-scan using a master scan time of 1.0 s. Dynamic exclusion was used to exclude ions for 20 s after two measurements within 30 s. Fragmentation was performed using stepped HCD collision energy of 15, 25 , and 35% at a resolution of 30,000, RF Lens 50 %, and AGC target 1e5, while full-scan resolution was set to 60,000.
Data analyses were performed with the software Xcalibur 3.1.2412.17 (Thermo Fisher Scientific Inc.).
